AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28443046 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 63
Study 28443046 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving Behavior Intervention (CBI)
Number of subjects: 63
Study 28444114 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg/day, orally) plus octreotide LAR (30 mg, intramuscularly, every 28 days)
Number of subjects: 429
Study 28444114 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus octreotide LAR (30 mg, intramuscularly, every 28 days)
Number of subjects: 429
Study 28444114 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus octreotide LAR
Number of subjects: 429
Study 28444156 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional intradermal doses of the inactivated poliovirus vaccine (ID fIPV)
Number of subjects: 0
Study 28444644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib
Number of subjects: 0
Study 28445112 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiregion whole-exome sequencing on 100 early-stage NSCLC tumors
Number of subjects: 100
Study 28445469 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic ctDNA profiling
Number of subjects: 100
Study 28445469 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative plasma ctDNA analysis
Number of subjects: 100
Study 28445469 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 100
Study 28445481 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aza-cytidine (AZA) at 500 nM
Number of subjects: 0
Study 28445481 — intervention group
Group type: EXPERIMENTAL
Intervention: AZA plus IRI
Number of subjects: 0
Study 28446129 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum RPR titer ≥1:4
Number of subjects: 370
Study 28446129 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TPPA titer ≥1:2560
Number of subjects: 370
Study 28446129 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel testing format of serum RPR titer ≥1:2 and serum TPPA titer ≥1:1280
Number of subjects: 370
Study 28446129 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 370
Study 28446129 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum creatine kinase
Number of subjects: 370
Study 28446129 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum RPR titer <1:2 and serum TPPA titer <1:1280
Number of subjects: 370
Study 28446135 — intervention group
Group type: EXPERIMENTAL
Intervention: ROM Plus®
Number of subjects: 111
Study 28446135 — intervention group
Group type: EXPERIMENTAL
Intervention: AmniSure®
Number of subjects: 111
Study 28446135 — intervention group
Group type: EXPERIMENTAL
Intervention: ROM Plus® (term patients ≥37 weeks)
Number of subjects: 111
Study 28446135 — intervention group
Group type: EXPERIMENTAL
Intervention: AmniSure® (term patients ≥37 weeks)
Number of subjects: 111
Study 28446135 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tests (preterm patients <37 weeks)
Number of subjects: 111
Study 28446181 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES-robot hybrid system
Number of subjects: 11
Study 28446181 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES applied to agonist muscles
Number of subjects: 11
Study 28446181 — intervention group
Group type: EXPERIMENTAL
Intervention: Device assisted upper limb training
Number of subjects: 11
Study 28446192 — intervention group
Group type: EXPERIMENTAL
Intervention: Trinity Evolution® (TE) viable cellular bone allograft
Number of subjects: 40
Study 28446244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 0
Study 28446244 — intervention group
Group type: COMPARATOR
Intervention: Further antiepileptic drugs (AED)
Number of subjects: 0
Study 28446419 — intervention group
Group type: EXPERIMENTAL
Intervention: SPPAC program (14 sessions, ~30 min each over 10 weeks) delivered by a peer trainer using a mobile phone
Number of subjects: 38
Study 28446419 — intervention group
Group type: COMPARATOR
Intervention: Existing PA guidelines
Number of subjects: 38
Study 28446421 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of processing training, a computerized Internet cognitive training program.
Number of subjects: 0
Study 28446421 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study 28446495 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume energy drink (946 mL, 320 mg caffeine)
Number of subjects: 18
Study 28446495 — intervention group
Group type: COMPARATOR
Intervention: Caffeinated control drink (320 mg caffeine)
Number of subjects: 18
Study 28446498 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet quality assessment
Number of subjects: 0
Study 28446501 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary long-chain fatty acids
Number of subjects: 0
Study 28446501 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28446521 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose
Number of subjects: 46
Study 28446560 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28447475 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaratumab plus doxorubicin
Number of subjects: 0
Study 28447475 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 0
Study 28448562 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADL)
Number of subjects: 595
Study 28448562 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 595
Study 28448562 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (ETN)
Number of subjects: 595
Study 28448562 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADL) and Infliximab (IFX)
Number of subjects: 595
Study 28448562 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (ETN, ADL, IFX)
Number of subjects: 595
Study 28448594 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVconsv vaccines
Number of subjects: 12
Study 28448662 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) followed by surgical resection in arm B (n=60)
Number of subjects: 252
Study 28448662 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy with FLOT in arm C (n=127)
Number of subjects: 252
Study 28448662 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with FLOT followed by surgery in arm B (n=36 who proceeded to surgery)
Number of subjects: 252
Study 28448662 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in arm B (n=60)
Number of subjects: 252
Study 28448662 — intervention group
Group type: COMPARATOR
Intervention: Patients in arm C (n=127)
Number of subjects: 252
Study 28449055 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus FOLFOX (PRIME)
Number of subjects: 675
Study 28449055 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus FOLFOX (PEAK)
Number of subjects: 675
Study 28449055 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX alone (PRIME)
Number of subjects: 675
Study 28449055 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus FOLFOX (PEAK)
Number of subjects: 675
Study 28449090 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute alcohol consumption (mean BAC 0.85 g/kg)
Number of subjects: 3028
Study 28449090 — intervention group
Group type: COMPARATOR
Intervention: Chronic alcohol consumption (KORA S4 Study)
Number of subjects: 3028
Study 28449352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziconotide as the first agent in pump (FIP+)
Number of subjects: 93
Study 28449352 — intervention group
Group type: COMPARATOR
Intervention: Not first intrathecal agent in pump (FIP-)
Number of subjects: 93
Study 28449642 — intervention group
Group type: EXPERIMENTAL
Intervention: Double incision technique
Number of subjects: 22
Study 28449642 — intervention group
Group type: COMPARATOR
Intervention: Single incision technique
Number of subjects: 22
Study 28449658 — intervention group
Group type: EXPERIMENTAL
Intervention: Movie Models online video intervention for parents, delivered over 4 weeks.
Number of subjects: 0
Study 28449674 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive chemotherapy
Number of subjects: 0
Study 28449675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever Assessment Tool (FAST)
Number of subjects: 68
Study 28449772 — intervention group
Group type: EXPERIMENTAL
Intervention: WiSE-CRT system (wireless left ventricular endocardial pacing)
Number of subjects: 35
Study 28449783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 28449783 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 28449809 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (part of the AcSé phase 2 trial, NCT02034981)
Number of subjects: 1
Study 28450272 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVIE en m@rche intervention (4-week intervention plus a brief booster at 8 weeks)
Number of subjects: 148
Study 28450272 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving hyperlinks to publicly available websites
Number of subjects: 148
Study 28450351 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (25 μg/kg; 1.5 mg if ≥60 kg)
Number of subjects: 80
Study 28450544 — intervention group
Group type: EXPERIMENTAL
Intervention: VWFA
Number of subjects: 33
Study 28450567 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor cells (CTCs)
Number of subjects: 0
Study 28450567 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cell-free DNA (cfDNA)
Number of subjects: 0
Study 28450894 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a 125 mcg every 2 weeks
Number of subjects: 1512
Study 28450894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1512
Study 28451922 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor Mothers (MM) conducting home visits
Number of subjects: 101
Study 28453532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed QM computerized working memory training (25 sessions, 5 days/week for 5 weeks)
Number of subjects: 9
Study 28453629 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid deployment aortic valve replacement with Edwards INTUITY valve system
Number of subjects: 295
Study 28453692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg intravenously every 2 weeks for up to 2 years or until progression or unacceptable toxicity
Number of subjects: 43
Study 28453697 — intervention group
Group type: COMPARATOR
Intervention: TNM staging alone
Number of subjects: 3016
Study 28453697 — intervention group
Group type: EXPERIMENTAL
Intervention: Models with added molecular markers (MSI, BRAFV600E, KRAS)
Number of subjects: 3016
Study 28453697 — intervention group
Group type: EXPERIMENTAL
Intervention: Models with clinicopathological features
Number of subjects: 3016
Study 28453697 — intervention group
Group type: EXPERIMENTAL
Intervention: Models with all covariates (TNM, molecular markers, clinicopathological features)
Number of subjects: 3016
Study 28453697 — intervention group
Group type: COMPARATOR
Intervention: TNM alone model
Number of subjects: 3016
Study 28453697 — intervention group
Group type: EXPERIMENTAL
Intervention: Models including clinicopathological features
Number of subjects: 3016
Study 28453697 — intervention group
Group type: EXPERIMENTAL
Intervention: TNM, clinicopathological features, and molecular markers
Number of subjects: 3016
Study 28453704 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and trastuzumab
Number of subjects: 48
Study 28453704 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-enriched subtype (RNA-seq analysis)
Number of subjects: 48
Study 28453704 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level or no ERBB2 amplification
Number of subjects: 48
Study 28453702 — intervention group
Group type: EXPERIMENTAL
Intervention: Motolimod combined with pegylated liposomal doxorubicin (PLD)
Number of subjects: 0
Study 28453702 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with pegylated liposomal doxorubicin (PLD)
Number of subjects: 0
Study 28453702 — intervention group
Group type: EXPERIMENTAL
Intervention: Motolimod (in subset analysis)
Number of subjects: 0
Study 28453702 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment in vitro responses of immune biomarkers to TLR8 stimulation
Number of subjects: 0
Study 28453702 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune score (tumor infiltrating lymphocytes; TIL), TLR8 single-nucleotide polymorphisms, mutational status in BRCA and other DNA repair genes, and autoantibody biomarkers
Number of subjects: 0
Study 28453773 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF GABA in women with PCOS
Number of subjects: 27
Study 28453773 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF testosterone in women with PCOS
Number of subjects: 27
Study 28453773 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF estradiol in women with PCOS
Number of subjects: 27
Study 28453773 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating testosterone in women with PCOS
Number of subjects: 27
Study 28453773 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating estradiol in women with PCOS
Number of subjects: 27
Study 28453773 — intervention group
Group type: COMPARATOR
Intervention: CSF glucose and glutamate concentrations
Number of subjects: 27
Study 28454122 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus irinotecan (IC)
Number of subjects: 18
Study 28454122 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus irinotecan and mitomycin C (ICM)
Number of subjects: 18
Study 28454122 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study 28454530 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based cohort
Number of subjects: 2141
Study 28454530 — intervention group
Group type: COMPARATOR
Intervention: Cohort with overweight/obesity
Number of subjects: 2141
Study 28454531 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based physical activity intervention program (225 min/week increase in physical activity, in addition to 90 min/week of ordinary PA)
Number of subjects: 1545
Study 28454531 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1545
Study 28454531 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based physical activity intervention program
Number of subjects: 1545
Study 28454793 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral access (TFA)
Number of subjects: 2028
Study 28454793 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 2028
Study 28454793 — intervention group
Group type: EXPERIMENTAL
Intervention: Left transradial access (left TRA)
Number of subjects: 2028
Study 28454793 — intervention group
Group type: EXPERIMENTAL
Intervention: Right transradial access (right TRA)
Number of subjects: 2028
Study 28454793 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of adjunctive protective pelvic drapes
Number of subjects: 2028
Study 28454793 — intervention group
Group type: EXPERIMENTAL
Intervention: Left projections and use of angiographic systems not dedicated for coronary and high frame rates
Number of subjects: 2028
Study 28454922 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once-monthly (PP1M)
Number of subjects: 334
Study 28454922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 28455173 — intervention group
Group type: EXPERIMENTAL
Intervention: Email reminders
Number of subjects: 2348
Study 28455173 — intervention group
Group type: COMPARATOR
Intervention: No email reminders
Number of subjects: 2348
Study 28455281 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine/topiramate extended release (ER)
Number of subjects: 3040
Study 28455281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3040
Study 28457013 — intervention group
Group type: EXPERIMENTAL
Intervention: e-health-based coagulation service (CS)
Number of subjects: 2318
Study 28457013 — intervention group
Group type: COMPARATOR
Intervention: Regular medical care (RMC)
Number of subjects: 2318
Study 28457485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine treatment
Number of subjects: 51
Study 28457485 — intervention group
Group type: COMPARATOR
Intervention: Placebo or baseline
Number of subjects: 51
Study 28457953 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-α treatment (recombinant human IFN-α-2b injections administered subcutaneously 2 to 3 times per week for 6 months)
Number of subjects: 107
Study 28457953 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-α treatment
Number of subjects: 107
Study 28458180 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP-1 mRNA expression in AgP patients
Number of subjects: 215
Study 28458180 — intervention group
Group type: COMPARATOR
Intervention: MCP-1 and CCR2 genotype distribution
Number of subjects: 215
Study 28458180 — intervention group
Group type: COMPARATOR
Intervention: MCP-1 and CCR2 allele frequencies
Number of subjects: 215
Study 28458770 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Herbal-based Cream
Number of subjects: 0
Study 28459071 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Fat Plant-Based Diet Supplemented with Plant-Based Meal Replacements
Number of subjects: 0
Study 28460039 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated high-sensitivity cardiac troponin T (hsTnT) levels (>14 ng/L)
Number of subjects: 2898
Study 28460039 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable hsTnT levels (5-14 ng/L)
Number of subjects: 2898
Study 28460039 — intervention group
Group type: COMPARATOR
Intervention: Undetectable hsTnT levels (<5 ng/L)
Number of subjects: 2898
Study 28460066 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib
Number of subjects: 5
Study 28460140 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T4 treatment
Number of subjects: 140
Study 28461298 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult-onset asthma patients with <10 smoked pack-years (never- and ex-smokers)
Number of subjects: 188
Study 28461298 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obstructive adult-onset asthma patients
Number of subjects: 188
Study 28461298 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 188
Study 28461396 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, 200 mg IV every 2 weeks, pomalidomide 4 mg daily for 21 days, dexamethasone 40 mg weekly
Number of subjects: 48
Study 28461396 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 48
Study 28461706 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with famotidine
Number of subjects: 2229
Study 28461706 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with pentoprazol
Number of subjects: 2229
Study 28461706 — intervention group
Group type: COMPARATOR
Intervention: Non-modifiable factors
Number of subjects: 2229
Study 28461706 — intervention group
Group type: COMPARATOR
Intervention: Modifiable factors
Number of subjects: 2229
Study 28461752 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 109
Study 28462685 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat exposure at 35°C for up to 120 minutes
Number of subjects: 8
Study 28464732 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (250 mg twice a day for 1 week, followed by 500 mg twice a day for 3 weeks)
Number of subjects: 20
Study 28464817 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative atrial fibrillation (poAF) group
Number of subjects: 62
Study 28464817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no poAF)
Number of subjects: 62
Study 28464817 — intervention group
Group type: EXPERIMENTAL
Intervention: eQTL analysis
Number of subjects: 62
Study 28464828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Number of subjects: 2047
Study 28464906 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant external beam radiotherapy (EBRT)
Number of subjects: 76
Study 28465125 — intervention group
Group type: EXPERIMENTAL
Intervention: High intact protein intake
Number of subjects: 86
Study 28465125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact protein intake
Number of subjects: 86
Study 28465125 — intervention group
Group type: EXPERIMENTAL
Intervention: Total protein maximized with medical foods (MF)
Number of subjects: 86
Study 28465125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counselling
Number of subjects: 86
Study 28465300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg orally twice a day for 10 days
Number of subjects: 22
Study 28465300 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg orally once a day for 10 days
Number of subjects: 22
Study 28465311 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate II support
Number of subjects: 200
Study 28465311 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical management
Number of subjects: 200
Study 28465315 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF5633 (synthetic surfactant)
Number of subjects: 40
Study 28465370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 6 mg/kg every 2 weeks
Number of subjects: 28
Study 28465370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 10 mg/kg every 3 weeks
Number of subjects: 28
Study 28465370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 8 mg/kg every 2 weeks
Number of subjects: 28
Study 28465454 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote foot-temperature monitoring system (thermometric foot mat)
Number of subjects: 132
Study 28465694 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS)
Number of subjects: 42
Study 28465824 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy according to the School of Manual Therapy Utrecht (MTU)
Number of subjects: 181
Study 28465824 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 181
Study 28466461 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 155
Study 28466461 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen
Number of subjects: 155
Study 28466557 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment in e14a2 patients
Number of subjects: 559